Phenotypic and immunomodulatory properties of equine cord blood-derived mesenchymal stromal cells.
Authors: Tessier Laurence, Bienzle Dorothee, Williams Lynn B, Koch Thomas G
Journal: PloS one
Summary
# Editorial Summary: Equine Cord Blood Mesenchymal Stromal Cells Mesenchymal stromal cells (MSCs) derived from equine umbilical cord blood represent a promising therapeutic tool for regenerative and immunomodulatory applications in horses, yet their consistency and functional properties require thorough characterisation before clinical translation. Koch's team successfully isolated MSCs from nine separate cord blood samples and comprehensively profiled their immunophenotype before and after cryopreservation, whilst simultaneously evaluating their capacity to suppress lymphoproliferation in vitro. The isolated cells displayed consistent marker expression (high CD29, CD44 and CD90; low/absent MHC class I and II, CD4, CD8 and CD73) regardless of cryopreservation status, and demonstrated significant anti-inflammatory potential through suppression of mixed lymphocyte reactions—findings substantiated by constitutive TLR4 expression. For practitioners considering MSC-based treatments, this research validates cord blood as a reliable and standardised cell source with documented immunosuppressive capabilities; however, the precise mechanisms linking toll-like receptor signalling to the cells' anti-inflammatory effects remain incompletely understood and warrant further investigation before optimising therapeutic protocols. The robustness of the isolation protocol and stability of phenotype across preservation cycles suggests cord blood MSCs could provide a reproducible cellular therapy platform, particularly valuable given the immunological complications associated with autologous bone marrow-derived alternatives.
Read the full abstract on PubMed
Practical Takeaways
- •Equine cord blood is a reliable and consistent source for obtaining MSC with immunomodulatory properties suitable for clinical application
- •MSC phenotype is preserved through cryopreservation, enabling storage and future therapeutic use without loss of key properties
- •The immunosuppressive capabilities of CB-MSC provide a scientific foundation for their use in inflammatory conditions, though further clinical trials are needed to establish efficacy
Key Findings
- •Equine cord blood MSC were successfully isolated from all 9 samples with consistent surface marker expression (high CD29, CD44, CD90; low/absent MHC-I, MHC-II, CD4, CD8, CD11a/18, CD73)
- •CB-MSC phenotype and marker expression remained stable before and after cryopreservation
- •CB-MSC suppressed in vitro lymphoproliferation, confirming immunosuppressive properties
- •CB-MSC constitutively expressed TLR4, suggesting an anti-inflammatory phenotype